ResMed Dividends and Buybacks
Dividend criteria checks 4/6
ResMed is a dividend paying company with a current yield of 0.86% that is well covered by earnings.
Key information
0.9%
Dividend yield
0.6%
Buyback Yield
| Total Shareholder Yield | 1.5% |
| Future Dividend Yield | 1.0% |
| Dividend Growth | 5.6% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | 22% |
Recent dividend and buyback updates
Recent updates
We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease
Sep 06
ResMed: A Dividend Opportunity In The MedTech Space As The Company Grows
Aug 27Calculating The Intrinsic Value Of ResMed Inc. (NYSE:RMD)
Jul 29Shareholders Would Enjoy A Repeat Of ResMed's (NYSE:RMD) Recent Growth In Returns
Jun 23Do ResMed's (NYSE:RMD) Earnings Warrant Your Attention?
Jun 11There's Reason For Concern Over ResMed Inc.'s (NYSE:RMD) Price
May 30ResMed (NYSE:RMD) Seems To Use Debt Rather Sparingly
May 18ResMed: Cornering The Market In Sleep Solutions
Apr 24ResMed Inc. (NYSE:RMD) Shares Could Be 32% Below Their Intrinsic Value Estimate
Apr 15If EPS Growth Is Important To You, ResMed (NYSE:RMD) Presents An Opportunity
Feb 26ResMed Inc.'s (NYSE:RMD) Share Price Not Quite Adding Up
Feb 14Revisiting ResMed In 2025: Strong Q2 Financial Results And The Growing Demand For Sleep Apnea Solutions
Feb 10ResMed: Snoozers Can Be Winners
Feb 01ResMed: Fully Valued With Medium-Term Challenges (Rating Downgrade)
Jan 24ResMed Inc.'s (NYSE:RMD) Intrinsic Value Is Potentially 45% Above Its Share Price
Jan 13ResMed (NYSE:RMD) Is Investing Its Capital With Increasing Efficiency
Jan 01ResMed: Solid Execution, Pricey Valuation
Nov 25Shareholders May Not Be So Generous With ResMed Inc.'s (NYSE:RMD) CEO Compensation And Here's Why
Nov 13We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease
Nov 01Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today
Oct 20ResMed Inc.'s (NYSE:RMD) Intrinsic Value Is Potentially 47% Above Its Share Price
Oct 08Why ResMed's Rally Is Just Getting Started
Sep 18ResMed: Asymmetrical Value Opportunity With High Prospect Of Re-Rating
Jul 03Stability and Growth of Payments
Fetching dividends data
Stable Dividend: RMD's dividends per share have been stable in the past 10 years.
Growing Dividend: RMD's dividend payments have increased over the past 10 years.
Dividend Yield vs Market
| ResMed Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (RMD) | 0.9% |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.4% |
| Industry Average (Medical Equipment) | 1.7% |
| Analyst forecast (RMD) (up to 3 years) | 1.0% |
Notable Dividend: RMD's dividend (0.86%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.43%).
High Dividend: RMD's dividend (0.86%) is low compared to the top 25% of dividend payers in the US market (4.44%).
Earnings Payout to Shareholders
Earnings Coverage: With its low payout ratio (22.2%), RMD's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its low cash payout ratio (21.2%), RMD's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/05 01:23 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ResMed Inc. is covered by 57 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | ANZ Equities Pty Limited |
| Michael Polark | Baird |
| David Rescott | Baird |